Taglich Brothers Neutral On Pressure BioSciences, Inc.

Taglich Brothers has a Neutral rating on shares of Pressure BioSciences, Inc. PBIO. In a note to clients, Taglich writes, "We are maintaining our Neutral rating on Pressure BioSciences PBIO due to heightened concerns about the company's ability to raise sufficient capital to sustain sales and R&D efforts in the near term. Risk of a NASDAQ Capital Market delisting (due to reduced stockholders' equity) could have an adverse effect on the stock's performance. PCT, a novel technology, has broad applications in genomics, proteomics and nucleic acid testing. With only 128 Barocyclers currently in service, an estimated 45,000 laboratories worldwide represent a significant long-term market opportunity. But under current circumstances, the growth we project through 2012 is not likely to support an attractive valuation." Shares of PBIO lost 2 cents yesterday to close at $1.05.